Home › Funds › EQUITY INVESTMENT CORP › GSK
EQUITY INVESTMENT CORP position in GSK
GSK PLC · Health Care
EQUITY INVESTMENT CORP reported holding 3,560,824 shares of GSK (GSK PLC) in its Q3 2026 13F filing — a position valued at US$171.5M, representing 3.23% of its reported portfolio and ranking #4 among its reported holdings. EQUITY INVESTMENT CORP has disclosed GSK holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How EQUITY INVESTMENT CORP's GSK position evolved
EQUITY INVESTMENT CORP first disclosed a stake in GSK in Q3 2023 at 3,277,362 shares (US$118.8M). The position peaked in Q4 2025 at 4,110,579 shares, worth US$201.6M. Across 13 filings, EQUITY INVESTMENT CORP increased the stake 8 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 3,560,824 shares valued at US$171.5M — an increase of 291,059 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 3.28M | $118.80M | New |
| Q4 2023 | 3.24M | $120.20M | Reduce |
| Q1 2024 | 3.40M | $145.70M | Add |
| Q2 2024 | 3.43M | $132.18M | Add |
| Q3 2024 | 3.50M | $142.93M | Add |
| Q4 2024 | 3.96M | $134.01M | Add |
| Q1 2025 | 4.17M | $161.71M | Add |
| Q2 2025 | 4.19M | $161.00M | Hold |
| Q3 2025 | 4.27M | $184.27M | Add |
| Q4 2025 | 4.11M | $201.58M | Reduce |
| Q1 2026 | 3.22M | $177.77M | Reduce |
| Q2 2026 | 3.27M | $171.40M | Add |
| Q3 2026 | 3.56M | $171.52M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GSK and 13F data
GSK (GSK PLC) is a Health Care company. 19 other funds we track also report a position in GSK — the largest reported positions include Dodge & Cox (US$2.53B), DODGE & COX (US$2.53B), PRIMECAP MANAGEMENT CO/CA/ (US$1.21B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GSK
- Dodge & Cox 48.20M sh · $2.53B · Q2 2026
- DODGE & COX 48.20M sh · $2.53B · Q2 2026
- PRIMECAP MANAGEMENT CO/CA/ 25.19M sh · $1.21B · Q3 2026
- JTC Employer Solutions Trustee Ltd 8.08M sh · $389.17M · Q3 2026
- Mondrian Investment Partners LTD 4.97M sh · $239.21M · Q3 2026
- Grantham, Mayo, Van Otterloo & Co. LLC 3.92M sh · $188.73M · Q3 2026
More on EQUITY INVESTMENT CORP
FAQ
How long has EQUITY INVESTMENT CORP held GSK?
EQUITY INVESTMENT CORP has disclosed GSK holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is EQUITY INVESTMENT CORP's current position in GSK?
As of Q3 2026, EQUITY INVESTMENT CORP holds 3.56M shares of GSK (GSK PLC), valued at $171.52M, representing 3.23% of its reported portfolio and ranking #4.
Has EQUITY INVESTMENT CORP been buying or selling GSK?
In the latest 13F filing (Q3 2026), EQUITY INVESTMENT CORP increased its position in GSK. The position peaked in Q4 2025 at 4.11M shares.
Which other funds hold GSK?
Other major institutional holders of GSK include Dodge & Cox, DODGE & COX, PRIMECAP MANAGEMENT CO/CA/, among 19 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.